Sheng Yao

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

Kristin J. Lastwika, Willie Wilson, Qing Kay Li et al. · Cancer Research · 2015 · 764 citations

Immunology, Immune Regulation, Immunoediting +20

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Takeshi Azuma, Sheng Yao, Gefeng Zhu et al. · Blood · 2008 · 536 citations · Full text

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Evan J. Lipson, William H. Sharfman, Charles G. Drake et al. · Clinical Cancer Research · 2012 · 535 citations

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 523 citations · Full text

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 466 citations · Full text